A Phase 1 clinical trial in healthy volunteers to assess the safety, pharmacokinetics and pharmacodynamic responses of RHX-317 as a novel therapeutic strategy to treat autoimmune and inflammatory diseases, including chronic graft-versus-host disease (cGVHD)
Latest Information Update: 22 Jul 2022
At a glance
- Drugs RHX-317 (Primary)
- Indications Graft-versus-host disease; Lupus nephritis; Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Rheos Medicines
Most Recent Events
- 20 Jul 2022 According to a Rheos Medicines media release, the U.S. Food and Drug Administration has given Study May Proceed letter to this trial under the Investigational New Drug (IND) application for RHX-317.
- 16 May 2022 New trial record